tiprankstipranks
Trending News
More News >
IN8bio (INAB)
NASDAQ:INAB

IN8bio (INAB) AI Stock Analysis

Compare
268 Followers

Top Page

IN

IN8bio

(NASDAQ:INAB)

32Underperform
IN8bio's overall stock score is driven primarily by its financial challenges, reflected in significant operational losses and reliance on external financing. Technical indicators highlight bearish sentiment, while valuation metrics indicate market skepticism about near-term profitability. These factors collectively result in a low overall score.
Positive Factors
Clinical Outcomes
INB-100 treated AML patients demonstrate 100% survival and complete remission at a median follow-up of 20.1 months.
Clinical Trial Progress
The INB-100 treatment has shown benefits beyond existing treatments while maintaining a clean safety profile with no severe side effects reported.
Financial Stability
Management expects the company's cash reserves to support operations until March 2026, indicating financial stability.
Negative Factors
Financial Risk
Capital overhang remains the key risk for INAB with approximately $15 million at the end of 3Q24.
Stock Dilution
The price target is lowered to $6 per share due to stock dilution.
Study Limitations
The data is from an open-arm single center study, which may limit the generalizability of the results.

IN8bio (INAB) vs. S&P 500 (SPY)

IN8bio Business Overview & Revenue Model

Company DescriptionIN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies for the treatment of cancer. The company operates in the biotechnology and healthcare sectors, leveraging its proprietary technology platform to create cell-based immunotherapies aimed at targeting both solid tumors and hematologic malignancies. IN8bio's core products are designed to harness the power of the immune system to recognize and attack cancer cells, offering potential therapeutic options for patients with limited treatment alternatives.
How the Company Makes MoneyIN8bio generates revenue primarily through collaborations and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships involve licensing agreements, milestone payments, and royalties linked to the development and commercialization of its proprietary gamma-delta T cell therapies. Additionally, the company may receive funding from grants and research support from governmental agencies or non-profit organizations interested in advancing cancer immunotherapy research. As IN8bio progresses towards commercialization, revenue streams may also include direct sales of approved therapies, pending successful clinical trials and regulatory approvals.

IN8bio Financial Statement Overview

Summary
IN8bio's financial performance reflects a typical biotechnology company in the developmental stage, with a strong reliance on external funding due to non-existent revenues and substantial operational losses. While the company has managed to secure financing to support operations, the declining equity and significant negative cash flows present financial stability challenges in the long term.
Income Statement
15
Very Negative
IN8bio has consistently reported zero revenue over the years, which is typical for early-stage biotechnology firms that rely on funding rather than sales. The company has reported increasing net losses annually, with a net income of -$30.4 million in the most recent year, reflecting significant operational expenses and R&D costs.
Balance Sheet
30
Negative
The company's balance sheet shows a declining stockholders' equity from $38.2 million in 2021 to $14.5 million in 2024, indicating substantial use of equity to fund operations. The debt-to-equity ratio has increased, reflecting increased reliance on debt despite a relatively low total debt level. The equity ratio has also decreased, indicating a higher proportion of liabilities in the capital structure.
Cash Flow
20
Very Negative
IN8bio's cash flow statements reveal large negative free cash flows, primarily due to substantial operating cash outflows. The company has been relying heavily on financing activities to fund its operations, as seen in significant financing cash inflows. This pattern highlights potential liquidity risks if external financing becomes unavailable.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
3.75M0.000.000.000.000.00
Gross Profit
1.86M0.00-2.50M-1.10M-251.00K-96.00K
EBIT
-31.88M-30.44M-30.34M-28.52M-14.65M-8.56M
EBITDA
-28.66M-30.44M-28.50M-27.42M-14.40M-8.47M
Net Income Common Stockholders
-31.88M-30.44M-30.01M-27.42M-14.65M-8.56M
Balance SheetCash, Cash Equivalents and Short-Term Investments
610.00K11.12M21.28M18.18M37.02M17.99M
Total Assets
1.13M20.94M33.71M33.04M42.22M20.91M
Total Debt
0.005.03M4.89M5.87M2.41M174.00K
Net Debt
-610.00K-6.09M-16.39M-12.31M-34.61M-17.82M
Total Liabilities
1.48M6.47M8.77M10.31M4.04M2.59M
Stockholders Equity
-346.00K14.48M24.94M22.73M38.18M18.32M
Cash FlowFree Cash Flow
-25.11M-24.25M-23.94M-27.83M-13.82M-7.13M
Operating Cash Flow
-24.97M-24.15M-23.34M-24.12M-13.51M-7.13M
Investing Cash Flow
-143.00K-187.00K-600.00K-3.71M-309.00K0.00
Financing Cash Flow
16.35M14.18M27.04M8.99M32.95M24.52M

IN8bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.15
Price Trends
50DMA
0.25
Negative
100DMA
0.27
Negative
200DMA
0.41
Negative
Market Momentum
MACD
-0.02
Positive
RSI
26.46
Positive
STOCH
11.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.25, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 26.46 is Positive, neither overbought nor oversold. The STOCH value of 11.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.

IN8bio Risk Analysis

IN8bio disclosed 77 risk factors in its most recent earnings report. IN8bio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IN8bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
$6.36B1.14-49.01%2.63%17.12%1.49%
48
Neutral
$983.63M-57.48%13698.99%31.46%
46
Neutral
$66.06M-273.36%194.23%45.50%
42
Neutral
$86.28M-54.21%-78.55%-0.92%
41
Neutral
$312.86M-55.13%-86.25%36.10%
36
Underperform
$32.49M41.08%-0.55%49.85%
32
Underperform
$12.28M-154.44%38.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INAB
IN8bio
0.15
-0.94
-86.24%
FATE
Fate Therapeutics
0.75
-5.96
-88.82%
KPTI
Karyopharm Therapeutics
3.86
-16.39
-80.94%
IOVA
Iovance Biotherapeutics
3.00
-10.07
-77.05%
ADAP
Adaptimmune Therapeutics
0.26
-1.10
-80.88%
ALLO
Allogene Therapeutics
1.44
-2.54
-63.82%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.